Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Inclusion Criteria:

• Informed consent obtained before any trial-related activities. Trial-relatedactivities are any procedures that are carried out as part of the trial, includingactivities to determine suitability for the trial

• BMI above or equal to 30 kg/m^2

• Male or female, age 18 years or older at the time of signing informed consent

Exclusion Criteria:

• HbA1c (glycosylated haemoglobin) above or equal to 6.5% (at screening visit), ordiagnosis of type 1 or type 2 diabetes mellitus

• Recent history of cardiovascular disease (myocardial infarction or stroke within thepast 6 months), severe congestive heart failure (NYHA class III, IV), or second degreeor greater heart block

• Personal or family history of Medullary Thyroid Carcinoma (MTC), or Multiple EndocrineNeoplasia type 2 (MEN2)

• Female who is pregnant, breast-feeding or intends to become pregnant or is ofchild-bearing potential and not using an adequate contraceptive method (adequatecontraceptive measure as required by local regulation or practice)

• Use in past 90 days of medications known to induce significant weight loss (e.g.,prescription weight loss medications) or weight gain (e.g., chronic use of oralsteroids, second generation antipsychotics)

• History of pancreatitis (acute or chronic)

• History of major depressive disorder within the past 2 years

• Any lifetime history of a suicide attempt

• Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to 110 mmHg)

• History of malignancy (except for non-melanoma skin cancer) within the past 5 years